可切除边缘性胰腺癌的新辅助治疗
Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.
作者信息
Barreto Savio George, Shrikhande Shailesh V, Sirohi Bhawna
机构信息
Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia Australia.
College of Medicine and Public Health, Flinders University, Adelaide, South Australia Australia.
出版信息
Indian J Surg Oncol. 2024 May;15(Suppl 2):249-254. doi: 10.1007/s13193-021-01361-1. Epub 2021 Jul 1.
Abstract
In this perspective, we present our assessment of all of the known accumulated evidence on the role of neoadjuvant therapy in the management of borderline resectable pancreatic cancer highlighting the gaps in the data, the current regimens used and providing a brief insight into the way forward.
摘要
从这个角度出发，我们对新辅助治疗在临界可切除胰腺癌管理中的作用的所有已知累积证据进行评估，突出数据中的差距、目前使用的治疗方案，并简要展望未来的方向。
相似文献
1
Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.可切除边缘性胰腺癌的新辅助治疗
Indian J Surg Oncol. 2024 May;15(Suppl 2):249-254. doi: 10.1007/s13193-021-01361-1. Epub 2021 Jul 1.
2
The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.新辅助治疗的肿瘤应激试验：对比新辅助治疗与直接切除治疗边界可切除胰腺腺癌的前瞻性研究系统综述。
Am Surg. 2024 Nov;90(11):3061-3073. doi: 10.1177/00031348241248703. Epub 2024 Apr 18.
3
Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.可切除边缘性胰腺癌及新辅助放化疗的作用
Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.
4
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.总新辅助 FOLFIRINOX 对比新辅助吉西他滨为基础的放化疗和辅助吉西他滨治疗可切除和交界可切除胰腺癌（PREOPANC-2 试验）：一项全国多中心随机对照试验的研究方案。
BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z.
5
Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program.在多中心社区肿瘤项目中实施针对可切除边缘性胰腺癌的标准化方法。
Surg Open Sci. 2020 Jul 29;2(4):25-31. doi: 10.1016/j.sopen.2020.07.003. eCollection 2020 Oct.
6
Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.新辅助治疗与直接手术治疗在可切除和临界可切除胰腺导管腺癌中的疗效比较：荟萃分析
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zrae172.
7
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
8
How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.新辅助治疗后如何处理胰腺癌：多排 CT 和肿瘤标志物评估可切除性。
Eur Radiol. 2022 Jan;32(1):56-66. doi: 10.1007/s00330-021-08108-0. Epub 2021 Jun 25.
9
Borderline resectable pancreatic cancer: on the edge of survival.可切除边缘的胰腺癌：处于生存边缘
Cancer Control. 2008 Oct;15(4):295-307. doi: 10.1177/107327480801500404.
10
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.局部进展期可切除胰腺导管腺癌的新辅助治疗。
Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8.
本文引用的文献
1
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.SWOG S1505 研究的手术结果：吉西他滨/白蛋白紫杉醇对比改良 FOLFIRINOX 用于可切除胰腺导管腺癌围手术期治疗的随机临床试验。
Ann Surg. 2020 Sep 1;272(3):481-486. doi: 10.1097/SLA.0000000000004155.
2
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.可切除及临界可切除胰腺癌的术前放化疗与直接手术对比：荷兰随机III期PREOPANC试验结果
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.
3
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.新辅助 FOLFIRINOX 方案在边界可切除胰腺癌患者中的应用：系统评价和患者水平的荟萃分析。
J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073.
4
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.影响边界性/局部进展期胰腺癌新辅助放化疗后疗效、围手术期结局及生存的因素。
Ann Surg. 2021 Feb 1;273(2):341-349. doi: 10.1097/SLA.0000000000003284.
5
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.新辅助治疗后手术改善交界性和局部进展期胰腺癌的生存：单中心经验。
Ann Surg. 2021 Mar 1;273(3):579-586. doi: 10.1097/SLA.0000000000003301.
6
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).对比有或无立体定向体部放射治疗的不同新辅助化疗方案治疗局部进展期胰腺癌的前瞻性随机Ⅱ期临床试验研究方案（BRPCNCC-1）。
Radiat Oncol. 2019 Mar 27;14(1):52. doi: 10.1186/s13014-019-1254-8.
7
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).吉西他滨与S-1新辅助化疗对比直接手术治疗可切除胰腺癌的随机II/III期试验（Prep-02/JSAP05）
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
8
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
9
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.诱导化疗后 FOLFIRINOX 方案联合放化疗对可切除交界性或局部进展期胰腺导管腺癌患者的疗效改善作用：AGEO-FRENCH 多中心队列研究。
Ann Surg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018 Oct 25.
10
Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.当代新辅助化疗时代边缘可切除胰腺癌患者的结局。
J Gastrointest Surg. 2019 Jan;23(1):112-121. doi: 10.1007/s11605-018-3966-8. Epub 2018 Sep 21.
Zotero 插件